HeartVista's one-click MRI software receives FDA clearance

The world of cardiac imaging received welcome news this week when HeartVista announced their One-Click MRI software received Food and Drug Administration clearance for use on Seimens Healthineers MRI scanners. 

It is HeartVista’s hope that their one-click cardiac localization method will make this modality more widely available to patients and providers. Data on their website suggests the AI-assisted scans are six times faster than standard cardiac MRIs (CMR), require fewer breath holds and can reduce image artifacts from arrhythmias by up to 12%.

 

Recent guidelines released jointly by the American Heart Association and the American College of Cardiology classified CMR as a class 1 recommendation for diagnosing patients with chest pain. However, due to the increased expense and time it takes to obtain such imaging, CMR has not yet been widely utilized. 

“One Click MRI clearance on Siemens Healthineers MRI scanners advances HeartVista’s mission of improving and increasing patient access to real-time MRI imaging, to enable better treatment decisions for physicians,” representatives wrote this.

You can read the full statement here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.